<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393677</url>
  </required_header>
  <id_info>
    <org_study_id>DN57/FM</org_study_id>
    <nct_id>NCT02393677</nct_id>
  </id_info>
  <brief_title>Supraclavicular Brachial Plexus Block Using Ropivacaine Alone and With Dexmedetomidine</brief_title>
  <official_title>Supraclavicular Brachial Plexus Block Using Ropivacaine Alone or Combined With Dexmedetomidine for Upper Limb Surgery: A Prospective, Randomized, Double-blinded, Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Government Medical College, Haldwani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Government Medical College, Haldwani</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      80 American Society of Anesthesiologists (ASA) grade I-II patients, 18-60 years old,scheduled&#xD;
      for elective upper limb orthopaedic surgery under supraclavicular brachial plexus block, were&#xD;
      included in this prospective study. The patients were randomly assigned to group R&#xD;
      (Ropivacaine alone) and group RD (Ropivacaine and dexmedetomidine) (40 patients in each&#xD;
      group). Group R received Ropivacaine 0.50% (30 cc) + placebo and group RD received&#xD;
      Ropivacaine 0.50% (30 cc) + dexmedetomidine 1 µg/kg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After Institutional Ethical Committee approval and written informed consent, a prospective,&#xD;
      randomized, double-blinded study was carried out on 80 ASA Grade I and II patients of either&#xD;
      sex, aged 18-60 years, undergoing various orthopaedic surgeries on the upper limb under&#xD;
      supraclavicular brachial plexus block. A power analysis was performed to determine the&#xD;
      necessary number of patients for each group based on duration of analgesia. With a 2-sided&#xD;
      type I error of 5% and study power at 80%, it was estimated that 38 patients would be needed&#xD;
      in each group in order to detect a difference of 35 min in the duration of analgesia between&#xD;
      the 2 groups. The study was conducted in two groups of 40 patients each. Patients were&#xD;
      randomly chosen by computer-generated random selection to one of the following groups:&#xD;
&#xD;
      Group R: Ropivacaine 0.50% (30 cc) + Placebo Group RD: Ropivacaine 0.50% (30 cc) +&#xD;
      Dexmedetomidine 1 µg/kg Randomization was performed by an independent statistician and&#xD;
      concealed from patients and investigators until completion of statistical analysis. Patients&#xD;
      were instructed preoperatively about use of the verbal rating scale (VRS) for pain assessment&#xD;
      (VRS: 0 = no pain, 10=worst pain possible). On arrival in the operation room, baseline heart&#xD;
      rate, blood pressure and oxygen saturation were recorded. An intravenous line was secured in&#xD;
      the unaffected limb and Ringer's lactate was started. Patients were given midazolam&#xD;
      intravenous (IV) (0.03 mg/kg) as premedication 10-15 min before beginning each blocks&#xD;
      technique. Subcutaneous injection with 2 mL of 2% lidocaine was administered at the needle&#xD;
      insertion site. All the patients received brachial plexus block through the supraclavicular&#xD;
      approach by an experienced anesthesiologist different from the one assessing the patient&#xD;
      intra- and post-operatively. Both were blinded to the treatment groups. Neural localization&#xD;
      was achieved by using a nerve locator (Stimuplex® Dig RC, B.Braun, Melsungen AG, Melsungen,&#xD;
      Germany) connected to a 22 G, 50-mm-long stimulating needle (Stimuplex, Braun, Germany). The&#xD;
      location end point was a distal motor response with an output lower than 0.5 milliampere&#xD;
      (mA).&#xD;
&#xD;
      Following negative aspiration, 30 mL of a solution containing local anesthetic combined with&#xD;
      placebo or dexmedetomidine as mentioned above was injected and the use of Dexmedetomidine was&#xD;
      off-label. A 5-min compression was performed to facilitate an even drug distribution. Sensory&#xD;
      blockade was assessed every 3 min and motor block was evaluated every 5 min within the first&#xD;
      30 min following completion of drug administration. Sensory block was confirmed by pinprick&#xD;
      sensation using a 23-G needle in all dermatomes of the brachial plexus (C5-T1) i.e. median&#xD;
      nerve, radial nerve, ulnar nerve and musculocutaneous nerve. Sensory onset was considered&#xD;
      when there was a dull sensation to pin prick along the distribution of any of these nerves&#xD;
      (Grade 1). Complete sensory block was considered when there was complete loss of sensation to&#xD;
      pin prick.&#xD;
&#xD;
      Sensory block was graded as- Grade 0 Sharp pin felt Grade 1 Analgesia, dull sensation felt&#xD;
      Grade 2 Anesthesia, no sensation felt&#xD;
&#xD;
      Motor blockade was evaluated by the ability to flex the elbow and hand against gravity as&#xD;
      follows :&#xD;
&#xD;
      Grade 1 Ability to flex and extend the forearm Grade 2 Ability to flex or extend only the&#xD;
      wrist and fingers Grade 3 Ability to flex or extend only the fingers Grade 4 Inability to&#xD;
      move the forearm, wrist, and fingers Onset of motor block was defined as the time from&#xD;
      injection of local anesthetic mixture until achieving a reduction in motor power to grade 3&#xD;
      or less. The block was considered incomplete when any of the segments supplied by median,&#xD;
      radial, ulnar and musculocutaneous nerve did not have analgesia even after 30 min of drug&#xD;
      injection. These patients were supplemented with intravenous fentanyl (2 μg/ kg) and&#xD;
      midazolam (0.03 mg/kg). When more than one nerve remained unaffected, it was considered a&#xD;
      failed block. In this case, general anesthesia was given intraoperatively. Patients were&#xD;
      monitored for hemodynamic variables such as heart rate, blood pressure and oxygen saturation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Analgesia</measure>
    <time_frame>upto 8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset of Sensory Block</measure>
    <time_frame>20 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of Motor Block</measure>
    <time_frame>30minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Motor Block</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Haemodynamic Changes</measure>
    <time_frame>8 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Complications</measure>
    <time_frame>2 hours</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Brachial Plexus Anesthesia</condition>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>amide local anesthetic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine with Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>combination of amide local anaesthetic and alpha2 agonist</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Ropivacaine 0.5% 30 ml was used to block brachial plexus</description>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>Ropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine with Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus</description>
    <arm_group_label>Ropivacaine with Dexmedetomidine</arm_group_label>
    <other_name>Ropin with Dextomid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  80 ASA Grade I and II patients of either sex, aged 18-60 years, undergoing various&#xD;
             orthopaedic surgeries on the upper limb under supraclavicular brachial plexus block.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  Patients with chronic pain (pain lasting more than 12 weeks)&#xD;
&#xD;
          -  Those using chronic analgesic medications (opioid, non steroidal anti-inflammatory&#xD;
             drugs, anticonvulsants, antidepressants)&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  History of brachial plexus injury&#xD;
&#xD;
          -  Allergy to the study drugs&#xD;
&#xD;
          -  Patients taking other medications with α-adrenergic blocking effect&#xD;
&#xD;
          -  Hepatic or renal insufficiency&#xD;
&#xD;
          -  Systemic infection or infection at the site of injection, and shoulder surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahin N Jamil, MD</last_name>
    <role>Study Director</role>
    <affiliation>Professor, Aligarh Muslim University</affiliation>
  </overall_official>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>March 15, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <results_first_submitted>April 17, 2015</results_first_submitted>
  <results_first_submitted_qc>October 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 6, 2015</results_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Government Medical College, Haldwani</investigator_affiliation>
    <investigator_full_name>Bikramjit Das</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ropivacaine</title>
          <description>amide local anesthetic&#xD;
Ropivacaine: Ropivacaine 0.5% 30 ml was used to block brachial plexus</description>
        </group>
        <group group_id="P2">
          <title>Ropivacaine With Dexmedetomidine</title>
          <description>combination of amide local anaesthetic and alpha2 agonist&#xD;
Ropivacaine with Dexmedetomidine: Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ropivacaine</title>
          <description>amide local anesthetic&#xD;
Ropivacaine: Ropivacaine 0.5% 30 ml was used to block brachial plexus</description>
        </group>
        <group group_id="B2">
          <title>Ropivacaine With Dexmedetomidine</title>
          <description>combination of amide local anaesthetic and alpha2 agonist&#xD;
Ropivacaine with Dexmedetomidine: Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.2" spread="9.6"/>
                    <measurement group_id="B2" value="34.52" spread="12.8"/>
                    <measurement group_id="B3" value="34.86" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Analgesia</title>
        <time_frame>upto 8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine</title>
            <description>amide local anesthetic&#xD;
Ropivacaine: Ropivacaine 0.5% 30 ml was used to block brachial plexus</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine With Dexmedetomidine</title>
            <description>combination of amide local anaesthetic and alpha2 agonist&#xD;
Ropivacaine with Dexmedetomidine: Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Analgesia</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413.73" spread="89.92"/>
                    <measurement group_id="O2" value="197.35" spread="28.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Onset of Sensory Block</title>
        <time_frame>20 minutes</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Onset of Motor Block</title>
        <time_frame>30minutes</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Motor Block</title>
        <time_frame>6 hours</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Haemodynamic Changes</title>
        <time_frame>8 hours</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Complications</title>
        <time_frame>2 hours</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ropivacaine</title>
          <description>amide local anesthetic&#xD;
Ropivacaine: Ropivacaine 0.5% 30 ml was used to block brachial plexus</description>
        </group>
        <group group_id="E2">
          <title>Ropivacaine With Dexmedetomidine</title>
          <description>combination of amide local anaesthetic and alpha2 agonist&#xD;
Ropivacaine with Dexmedetomidine: Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bikramjit Das</name_or_title>
      <organization>Govt. Medical College, Haldwani.</organization>
      <phone>(05946)-228393</phone>
      <email>bikramjit_81@rediff.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

